Climb Bio is in a technical breakout with an attractive headline valuation and strong upside to analyst targets, but sub-floor business quality, inconsistent earnings, and a purely speculative small-cap classification keep conviction and position sizing at essentially zero.
Thesis pillars
- Golden Cross Technical Breakout→Stable
- Attractive Valuation Vs Analyst Targets→Stable
- Quality Deficit From Cash Burn→Stable
- +2 more pillars — see the Why tab for full reasoning
Pillars as of Jul 5, 2026, based on the 10-K filed Mar 5, 2026
Climb Bio, Inc. (CLYM) Stock Analysis
Range Bound setup · Inst Constrain edge
Healthcare · Biotechnology
Sell if holding. Engine safety override at $10.25: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.5/10 and A.R:R 9.7:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 24%; Below-average business quality; Below long-term trend.
Climb Bio is a clinical-stage biotechnology company developing budoprutug, an anti-CD19 monoclonal antibody in Phase 1b/2 trials for primary membranous nephropathy, immune thrombocytopenia and systemic lupus erythematosus, and CLYM116, an anti-APRIL antibody for IgA nephropathy... Read more
Sell if holding. Engine safety override at $10.25: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.5/10 and A.R:R 9.7:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 24%; Below-average business quality; Below long-term trend. Chart setup: RSI 46 mid-range, Bollinger mid-band. Score 5.5/10, moderate confidence.
Passes 5/9 gates (positive momentum, favorable risk/reward ratio, news events none recent, semi cycle peak clear, materials cycle peak clear). Suitability: speculative.
About Climb Bio, Inc.
About Climb Bio, Inc.
Climb Bio is advancing budoprutug, an anti-CD19 monoclonal antibody, through Phase 1b/2 trials in primary membranous nephropathy (pMN), immune thrombocytopenia (ITP) and systemic lupus erythematosus (SLE), alongside CLYM116, an anti-APRIL antibody for IgA nephropathy licensed from Mabworks in January 2025. The company reported a $59.9 million net loss for 2025 against a $289.7 million accumulated deficit, with $160.7 million in cash and marketable securities as of December 31, 2025 that management expects will fund operations into 2028.
Climb Bio has no approved products and generates no product revenue; its entire near-term value rests on clinical execution across two licensed assets. Budoprutug dosed its first PrisMN Phase 2 patient in pMN in November 2025 after Phase 1b data showed three of five patients achieved complete remission of proteinuria, and separate Phase 1b/2a and Phase 1b trials are enrolling in ITP and SLE, respectively, alongside a China-specific SLE trial cleared in December 2025. CLYM116 entered a Phase 1 healthy-volunteer trial in November 2025, while partner Mabworks separately began a Phase 1/2 trial in China evaluating IgA nephropathy patients under the January 2025 Mabworks Agreement, which grants Climb rights to CLYM116 outside Greater China. The company also carries legacy license obligations assumed through its acquisition of Tenet Medicines, including the Asset Purchase Agreement, CRH Agreement and ProBioGen Agreement, each of which can require milestone and royalty payments.
Show full overview
Climb Bio's own risk factors state plainly that the company is substantially dependent on the success of budoprutug and CLYM116, with no other late-stage assets to fall back on if either program fails in the clinic or at the FDA. That dependency is compounded by licensing risk: the 10-K warns that failing to meet payment or diligence obligations under its license agreements could result in the loss of rights to budoprutug, CLYM116 or any other product candidate it licenses, meaning Climb's core assets are contractually revocable rather than owned outright, a distinct exposure from companies that control their pipeline IP free and clear.
See also: Healthcare · Biotechnology
From Climb Bio, Inc.'s most recent 10-K filing, extracted July 6, 2026.
Recent developments
updated 2026-11-02Recent Developments — Climb Bio, Inc.
Latest news
- NEWS BTIG Reiterates Buy on Climb Bio, Maintains $32 Price Target — benzinga Oct 27, 2026 positive
- NEWS Reported Saturday, Climb Bio Reports Initial PrisMN Phase 2 Data Showing 200 mg Budoprutug Delivered 70% Mean PLA2R Anti — benzinga Oct 26, 2026 positive
- NEWS Climb Bio Presents Initial PrisMN Phase 2 Data for Budoprutug at ASN Kidney Week 2026 — fiscal.ai Oct 24, 2026 positive
- NEWS Climb Bio and Mabworks Announce CLYM116/MIL116 Data at ASN Kidney Week 2026 — fiscal.ai Oct 23, 2026 positive
- NEWS Climb Bio And Mabworks Report Phase 1 Data Supporting Quarterly CLYM116/MIL116 Dosing For IgA Nephropathy; Phase 3 Trial — benzinga Oct 23, 2026 positive
Generated 2026-11-02T11:53:15Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHpipelinebudoprutug and CLYM116 (entire clinical pipeline)10-K Item 1A: 'We do not have any product candidates that have gained regulatory approval, and we are substantially dependent on the success of budoprutug and CLYM116.'
- HIGHcounterpartyproduct candidate licensors (including Mabworks)10-K Item 1A: 'If we fail to meet payment or diligence obligations, licensors may terminate the agreements, resulting in the loss of rights to budoprutug, CLYM116 or any other product candidate we may license.'
Material Events(8-K, last 90d)
- 2026-07-01Item 5.02LOWDirector Andrew Levin resigned from the Board effective June 29, 2026; Breanna O'Reilly, Ph.D. was elected to replace him the same day, to serve until the 2027 annual meeting. Routine board transition, no dispute cited.SEC filing →
- 2026-06-08Item 5.02LOWAt the June 5, 2026 annual meeting, stockholders approved an amendment to the 2021 Equity Incentive Plan to include prefunded warrants in the automatic share-pool increase calculation. Routine equity-plan amendment, not an executive or director departure.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers·1 ceiling hit
Quality below the gate floor. Component breakdown shows what dragged the score down.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $10.25: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.5/10 and A.R:R 9.7:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 24%; Below-average business quality; Below long-term trend. Chart setup: RSI 46 mid-range, Bollinger mid-band. Prior stop was $9.53. Score 5.5/10, moderate confidence.
Analyst target: $25.08 (+144.7% upside). Prior stop was $9.53. Stop-loss: $9.53.
Concentration risk — Pipeline: budoprutug and CLYM116 (entire clinical pipeline); Concentration risk — Counterparty: product candidate licensors (including Mabworks); Quality below floor (1.6 < 4.0).
Climb Bio, Inc. trades at a P/E of N/A (forward -10.2). TrendMatrix value score: 9.0/10. Verdict: Sell.
22 analysts cover CLYM with a consensus score of 4.4/5. Average price target: $28.
What does Climb Bio, Inc. do?Climb Bio is a clinical-stage biotechnology company developing budoprutug, an anti-CD19 monoclonal antibody in Phase...
Climb Bio is a clinical-stage biotechnology company developing budoprutug, an anti-CD19 monoclonal antibody in Phase 1b/2 trials for primary membranous nephropathy, immune thrombocytopenia and systemic lupus erythematosus, and CLYM116, an anti-APRIL antibody for IgA nephropathy licensed from Mabworks outside Greater China. The company has no approved products or product revenue, reported a $59.9 million net loss in 2025, and had $160.7 million in cash and marketable securities expected to fund operations into 2028.